Möchten Sie immer auf dem neuesten Stand bleiben?

Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide

Wegovy® pill showed 21.6% weight loss in early responders and improved mobility in OASIS-4 data at ECO2026.

Felix to lower semaglutide pricing by up to 65% as generic options enter Canada, helping improve affordability for weight management patients.

Novo Nordisk today announced data demonstrating that Wegovy® delivers substantial and consistent weight-loss results for women.

Novel alternative to GLP-1 drugs: Phase I data demonstrate fat mass reduction, preservation of lean mass, 80% responder rate, and no serious adverse events

Novo Nordisk will present new clinical data and real-world evidence at the European Congress on Obesity, 12–15 May in Istanbul, Turkey.

NorthStrive Biosciences Announces U.S. Arrival of EL-32 Working Cell Bank and Initiation of Manufacturing Optimization for Dual Myostatin Assets Targeting

US FDA has approved Wegovy® HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight reduction long-term.

Northstrive Biosciences Announces Launch of EL-32 Preclinical Study Evaluating Muscle Preservation in GLP-1 Weight Loss Therapy

NorthStrive Biosciences Signs Definitive License Agreement for Commercialization of EL-22 and EL-32, a Myostatin-Engineered Probiotic for Muscle Preservati